Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA, and Chair of the Melanoma Committee at SWOG. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered T cells, PD-1 blockade and BRAF targeted therapies. His National Cancer Institute (NCI), State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options, studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. Dr. Ribas is an elected member of the American Society of Clinical Investigation (ASCI), has a Doctor Honoris Causa from the University of Buenos Aires, the recipient of the 2014 AACR Richard and Hinda Rosenthal Award, the 2018 AACR-CRI Lloyd J. Old Award in Cancer Immunology and a NCI Outstanding Investigator Award.
Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician in Chief, Distinguished Professor Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Senior Consultant, Clinical Investigations for the City of Hope; Chief Scientific Officer for HonorHealth Research Institute; Medical Director of Research, Chief Scientific Officer, US Oncology, and Professor of Medicine, Mayo Clinic.
Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegibm, nab-paclitaxel, nal-IRI, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.
Dr. Von Hoff has published more than 690 papers, 140 book chapters and over 1400 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.
Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.
Dr. David Mankoff is Gerd Muehllehner Professor of Radiology, Vice-Chair for Research in Radiology, and Director of the PET Center at the Perelman School of Medicine at the University of Pennsylvania. Dr. Mankoff is board-certified in Nuclear Medicine and holds a PhD in Bioengineering focusing on PET instrumentation. He practices Nuclear Medicine at the University of Pennsylvania, with a special interest in oncologic applications of molecular imaging and radionuclide treatment of endocrine tumors and other cancers. Dr. Mankoff’s research focuses on molecular imaging of cancer, primarily on breast cancer, and emphasizes therapeutic monitoring, identifying factors mediating therapeutic resistance, and the translation of new methods to clinical trials. He also focuses on imaging methodology and quantitative imaging methods related to molecular cancer imaging. Dr. Mankoff is a Komen Scholar for the Susan G. Komen Foundation. He also Chairs the Experimental Imaging Sciences Committee and serves as Co-Chair of the Scientific Program Committee of ECOG-ACRIN. Dr. Mankoff is a past member and President of the American Board of Nuclear Medicine. Dr. Mankoff is on the editorial boards of Nuclear Medicine and Biology, Breast Cancer Research, Journal of Nuclear Medicine, The Breast Journal, and Clinical Cancer Research and serves as an Associate Editor for Breast Cancer Research and the Journal of Nuclear Medicine.